Open AccessEfficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
Author(s) -
Wenxia Hu,
Jingcui Peng,
Yun Wang,
Jian Hao,
Ning Geng
Publication year - 2022
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s350771
Subject(s) - medicine , gefitinib , lung cancer , adverse effect , progressive disease , retrospective cohort study , oncology , univariate analysis , proportional hazards model , subgroup analysis , response evaluation criteria in solid tumors , log rank test , gastroenterology , multivariate analysis , cancer , epidermal growth factor receptor , disease , confidence interval
This study was to investigate the efficacy and safety of gefitinib plus anlotinib for patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line setting.